Coenzyme Q10 in Pediatric Community-Acquired Pneumonia

December 18, 2025 updated by: Rehab Zaki Elmeazawy, Tanta University

Coenzyme Q10 as an Adjunct Therapy in Pediatric Community-Acquired Pneumonia

The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
    • Gharbia Governorate
      • Tanta, Gharbia Governorate, Egypt, 37515
        • Tanta University
        • Contact:
          • Rehab Zaki Elmeazawy
          • Phone Number: 01004815280
        • Contact:
        • Principal Investigator:
          • Rehab Zaki Elmeazawy, MD
        • Sub-Investigator:
          • Ahmed Elniny Ahmedelniny8@gmail.com, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • All children aged 2 months -18 years with community acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x ray indicating community acquired pneumonia

Exclusion Criteria:

  • Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders, children with CHD affecting the pulmonary blood flow.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 60 children with community acquired pneumonia will receive oral coenzymeQ10
Drug: oral coenzymeQ10
60 children with community acquired pneumonia will receive oral coenzymeQ10 in capsule form at a dose of 100-200 mg/kg/day, as adjunct therapy to the usual pneumonia treatment till the recovery of the disease.
No Intervention: 60 children with community acquired pneumonia with the standard pneumonia treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Normalization of respiratory rate
Time Frame: 3 days
3 days
Normalization of temperature
Time Frame: 3 days
3 days
Normalization of oxygen saturation
Time Frame: 3 days
3 days
Normalization of Feeding Behavior Assessed by Oral Intake Tolerance
Time Frame: 3 days
Normalization of feeding refusal will be assessed by evaluating the child's ability to tolerate age-appropriate oral feeding without refusal over a 3-day observation period.
3 days
Serum C-Reactive Protein (CRP) Level
Time Frame: 5 days
Blood samples will be collected, and CRP concentration will be expressed in milligrams per liter (mg/L).
5 days
Serum Lactate Dehydrogenase (LDH) Level
Time Frame: 5 days
LDH concentration will be reported in units per liter (U/L) from venous blood samples.
5 days
Prognostic Nutritional Index
Time Frame: 5 days
5 days
Systemic Immune-Inflammation Index
Time Frame: 5 days
5 days
Serum C-Reactive Protein to Albumin Ratio (CRP/Albumin Ratio)
Time Frame: 5 days
The serum C-reactive protein to albumin ratio (CRP/albumin ratio) will be calculated as a single composite outcome measure using laboratory values obtained from the same blood sample.
5 days
Time of clinical stability
Time Frame: 3-5 days
3-5 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of hospital stay
Time Frame: 10-21 days
10-21 days
Number of Participants Requiring Surgical Intervention
Time Frame: 21-30 days

This outcome measures whether a participant undergoes any surgical intervention related to the study condition during the follow-up period. Surgical intervention is defined as any operative procedure performed under general or regional anesthesia, as documented in the medical record.

The outcome will be recorded as a binary variable (Yes/No) for each participant and summarized as the number and proportion of participants requiring surgical intervention.
21-30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tanta University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 31, 2025

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

June 9, 2025

First Submitted That Met QC Criteria

December 18, 2025

First Posted (Actual)

January 5, 2026

Study Record Updates

Last Update Posted (Actual)

January 5, 2026

Last Update Submitted That Met QC Criteria

December 18, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 36264PR1169/3/25

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe